MDT targets metastases with high-dose ablative radiation therapy, aiming to eliminate all cancer cells at all sites identified on a scan.

MDT has emerged as a major area of research after a successful initial study at MD Anderson in 2016 demonstrated its effectiveness for patients with lung cancer.

The Barbara Ann Karmanos Cancer Institute welcomes Wasif Saif, M.D., MBBS, as the new leader of the Phase 1 Clinical Trials Multidisciplinary Team and co-leader of the Gastrointestinal (GI) and ...

MDT has emerged as a major area of research after a successful initial study at MD Anderson in 2016 demonstrated its effectiveness for patients with lung cancer.

A previous report from the study showed that adding MDT to systemic therapy led to significant improvement in PFS for patients with oligometastatic prostate cancer.

This award highlights the exceptional work of oncology clinicians practicing in a community setting Targeted Oncology is pleased to announce this year’s first recipient of the Oncology Icons ...

Icon Oncology, the leading cancer care provider in the country, recently celebrated the installation of a cutting-edge linear accelerator (Linac) at its radiation therapy unit in Benoni. This ...

Chris Smyth, President of ICON Biotech, commented, “Biotechs play an important role in driving the field of oncology therapeutics forward.

The Barbara Ann Karmanos Cancer Institute welcomes Hassan Nasser, M.D., an otolaryngologist and surgical oncologist who specializes in head and neck cancers. Dr. Nasser is part of the Head and Neck ...

ICON shares results of a survey of over 100 oncology drug development professionals on the current state of emerging oncology treatment development.

ICON plc, a world-leading clinical research organisation powered by healthcare intelligence, today announced results from a recent survey of over 100 professionals engaged in oncology drug ...